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Abstract
Background: Aripiprazole, a second-generation antipsychotic medication, has been increasingly used in the maintenance
treatment of bipolar disorder and received approval from the U.S. Food and Drug Administration for this indication in 2005.
Given its widespread use, we sought to critically review the evidence supporting the use of aripiprazole in the maintenance
treatment of bipolar disorder and examine how that evidence has been disseminated in the scientific literature.
Methods and Findings: We systematically searched multiple databases to identify double-blind, randomized controlled
trials of aripiprazole for the maintenance treatment of bipolar disorder while excluding other types of studies, such as open-
label, acute, and adjunctive studies. We then used a citation search to identify articles that cited these trials and rated the
quality of their citations. Our evidence search protocol identified only two publications, both describing the results of a
single trial conducted by Keck et al., which met criteria for inclusion in this review. We describe four issues that limit the
interpretation of that trial as supporting the use of aripiprazole for bipolar maintenance: (1) insufficient duration to
demonstrate maintenance efficacy; (2) limited generalizability due to its enriched sample; (3) possible conflation of
iatrogenic adverse effects of abrupt medication discontinuation with beneficial effects of treatment; and (4) a low overall
completion rate. Our citation search protocol yielded 80 publications that cited the Keck et al. trial in discussing the use of
aripiprazole for bipolar maintenance. Of these, only 24 (30%) mentioned adverse events reported and four (5%) mentioned
study limitations.
Conclusions: A single trial by Keck et al. represents the entirety of the literature on the use of aripiprazole for the
maintenance treatment of bipolar disorder. Although careful review identifies four critical limitations to the trial’s
interpretation and overall utility, the trial has been uncritically cited in the subsequent scientific literature.
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First-generation antipsychotic medications have been used for
many decades in the short-term treatment of acute manic episodes
associated with bipolar disorder [1]. Second-generation antipsy-
chotic medications have increasingly gained popularity for this use
as well [2]. However, their promotion for the maintenance
treatment of bipolar disorder is a more recent phenomenon [3–6].
In one recently published nationally representative survey of
physicians, mood disorders accounted for the majority of
antipsychotic medication prescriptions [7], and a recent shift to
prescription of antipsychotic medications was observed in a sample
of San Diego county Medicaid beneficiaries with bipolar disorder
[8].
Traditionally, the clinical care of patients diagnosed with
bipolar disorder has been divided into three phases (borrowed
from clinical consensus about the phases of treatment for major
depressive disorder [9,10]): treatment of acute episodes to
symptomatic remission, continuation treatment to prevent relapse,
and maintenance treatment to prevent recurrence. The 2 mo
following recovery from the acute episode is commonly described
as acute phase recovery, and the continuation phase of treatment
(during which the natural course of the episode is considered still
active even though the patient may be asymptomatic) is defined as
lasting from months 2 through 6 [11,12]. The medication used for
treatment in the acute phase is often extended for treatment in the
continuation and maintenance phases [13,14] and in this context
may include lithium, valproate, lamotrigine, or a second-
generation antipsychotic medication such as olanzapine, aripipra-
zole, quetiapine, risperidone, or ziprasidone [15]. However,
although the use of second-generation antipsychotic medications
to treat acute mania is supported by a relatively well-established
evidence base [16–18], efficacy in treatment of acute mania does
not necessarily imply efficacy for maintenance or prophylaxis
[13,19,20]. As Goodwin and Jamison note: ‘‘Simply because a
drug has anti-manic properties (and if continued, will protect
against relapse back into mania in the months after the acute
episode), one cannot assume that it will be effective in the
prevention of new episodes. While this assumption may be true (to
some extent) for lithium, it is not well supported by the data with
respect to all the other antimanic agents’’ (p. 800) [21].
Despite the need for robust evidence on the maintenance and/
or long-term prophylactic treatment of bipolar disorder, to date
very little has been supplied in this regard [4,15,22,23]. There
remains little consensus about recommended courses of mainte-
nance or prophylactic treatment, and consequently overall
psychopharmacological treatment patterns vary widely [24–28].
Aripiprazole, first approved by the U.S. Food and Drug
Administration (FDA) for the treatment of schizophrenia in
2002, is the newest of the second-generation antipsychotic
medications to have obtained FDA approval for use in bipolar
disorder. In 2004 it was approved for the treatment of acute manic
and mixed episodes associated with bipolar disorder, and in 2005
it was granted an additional indication for the maintenance
treatment of bipolar disorder [29]. Since its approval, aripiprazole
has rapidly become a popular choice among clinicians in the
maintenance treatment of bipolar disorder. Total U.S. sales for
aripiprazole (across all indications) increased from US$1.5 billion
in 2005 to US$4 billion in 2009 [30]. In a recent study in which
U.S.-based physicians were queried about their preferred
pharmacological treatments for schizophrenia and bipolar disor-
der, only 3% of psychiatrists and 7% of primary care physicians
named aripiprazole as their first choice for treating schizophrenia,
whereas 23% of psychiatrists and 16% of primary care physicians
named aripiprazole as their first choice for treating bipolar
disorder [31]. Consistent with this survey, from 2002–2007, the
most common indication for the prescription of aripiprazole in
office-based practice settings was for bipolar disorder (Interna-
tional Classification of Diseases, Ninth Revision, Clinical Modi-
fication [ICD-9-CM] Diagnosis Code 296.0) [32].
In the setting of chronic illnesses such as bipolar disorder,
critical appraisal of long-term treatments has important implica-
tions for policy making. Overall medication costs for the
chronically ill are driven largely by decisions about the ongoing
use of prescription medications, rather than by decisions about
whether to initiate their use [33]. Spending on prescription
medications is the fastest-growing category of the U.S. health care
budget [34], further underscoring the need for a rigorous
evidence-based approach regarding their prescription and use.
Given the rapid adoption and widespread use of aripiprazole in
the maintenance treatment of bipolar disorder, we decided to
review the scientific data supporting its use in this setting. A
secondary aim of this study was to examine the diffusion of this
data into the subsequent scientific literature.
Methods
Primary Evidence Search
We sought to identify double-blind (i.e., where participants and
physicians administering medications were blind to treatment
assignment), randomized controlled studies of aripiprazole for the
maintenance treatment of bipolar disorder, while also avoiding
inadvertent inclusion of acute treatment studies or other study
designs. Therefore we required studies to have a duration greater
than 4 mo in order to be included in our review, and excluded
open-label, acute, and adjunctive studies. We searched for
published literature as well as unpublished and ongoing clinical
trials, with no language restrictions. The following systematic
search strategy was employed to search PubMed: ‘‘bipolar
disorder’’[MeSH Terms] OR (‘‘bipolar’’[All Fields] AND ‘‘dis-
order’’[All Fields]) OR (‘‘bipolar disorder’’[All Fields]) AND
(‘‘aripiprazole’’[Substance Name] OR ‘‘aripiprazole’’[All Fields])
AND (‘‘maintenance’’[MeSH Terms] OR ‘‘maintenance’’[All
Fields]). We also searched Scopus (including Embase and
MEDLINE) using the same search terms (‘‘bipolar disorder’’
OR ‘‘bipolar’’ AND ‘‘disorder’’ AND ‘‘aripiprazole’’ AND
‘‘maintenance’’). We also searched ClincalTrials.gov, the Co-
chrane Central Register of Controlled Trials (Issue 3 of 4, July
2010), and the World Health Organization International Clinical
Trials Registry Platform Search Portal using the terms ‘‘aripipra-
zole’’ and ‘‘bipolar.’’ We did not attempt to contact the
manufacturer directly to inquire about possibly unpublished trials,
but we screened all listings on the Bristol-Myers Squibb Clinical
Trials Disclosure Web site under Clinical Trial Results, Psychiatric
Disorders [35]. All searches were conducted in July 2010. And
finally, we submitted a request under the U.S. Freedom of
Information Act [36] for the supplemental New Drug Application
(NDA) filed by the study sponsor to obtain additional labeling for
the use of aripiprazole as maintenance therapy in bipolar I
disorder [29], and we searched it manually for further reference to
other published or unpublished studies.
Citation Search
We also sought to better understand the influence of the
primary evidence on the broader scientific literature. To do this,
we used the Web of Science(R) Science Citation Index Expanded
Aripiprazole for Bipolar Maintenance
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through the evidence search protocol detailed above. Next, we
evaluated the articles on how they cited the primary evidence,
using criteria similar to those used in a previous study on the
quality of news media reports of medication trials [37]. Each of the
citing articles was rated on three quality criteria by a single study
author (NZR). A 15% random sample of articles (n=15) was
double-coded independently by another study author (ACT), and
the Cohen’s kappa coefficient was calculated in order to assess the
degree of inter-rater agreement [38]. We chose dichotomous
quality ratings to provide conservative estimates of citation quality
and in order to limit subjective judgments by the rater. First,
articles were screened for any mention of the use of aripiprazole
specifically for ongoing, maintenance, or prophylactic treatment of
bipolar disorder. If the answer to this question was ‘‘yes,’’ then the
article was further rated on the three quality criteria: (1) whether
the article reported any quantitative data from the primary
evidence (e.g., odds ratios, percentages, or p-values); (2) whether
the article mentioned any adverse events described in the primary
evidence; and (3) whether the article mentioned any limitations of
the primary evidence.
Although our citation search protocol was not specifically
targeted towards identifying treatment guidelines and review
articles on pharmacological treatment strategies in bipolar
disorder, we manually highlighted for further discussion those
that were identified in the citation search. Our citation search
protocol likely underestimates the influence of the primary
evidence because we did not also use a database such as Google
Scholar that could have also identified guidelines implemented by
hospitals, government, or other institutions whose documents in
this area have not been published in peer-reviewed journals or
indexed in services such as PubMed. However, we chose to
highlight treatment guidelines and reviews because they can be
particularly influential in shaping prescribing behavior.
Results
Our primary evidence search protocol identified 177 unique
citations (Figure 1). Of these 177 citations, only two publications
met criteria for inclusion in our review [39,40]. Searching the
clinical trials registries yielded two listings meeting inclusion
criteria, but these referred to the two publications already
identified (Figure 2) [39,40]. Further details on the excluded acute
and adjunctive studies are provided in Tables S1 and S2. Two
unpublished trials initially appeared to meet criteria for inclusion
but were ultimately excluded. The first, Otsuka NCT00606177
[41], was a 3-wk placebo-controlled trial of aripiprazole for
treatment of acute mania with a 22-wk extension phase, but it was
described as currently still recruiting study participants. The
second, BMS CN138-135LT [42], was a completed 40-wk
extension of a 12-wk randomized lithium- and placebo-controlled
trial of aripiprazole for acute mania. Although the 12-wk acute
outcomes data from BMS CN138-135 were published in a peer-
reviewed journal [43], the outcomes data from the 40-wk
extension have not, to our knowledge, been published (and the
little data made available in the synopsis posted online by the
Figure 1. Publications identified for review. These publications were identified using a systematic search of PubMed and Scopus, as well as a
manual search of the supplemental new drug application submitted to the FDA to obtain an additional indication for the use of aripiprazole in the
maintenance treatment of bipolar disorder.
doi:10.1371/journal.pmed.1000434.g001
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The manufacturer’s synopsis indicates that 4.5% of participants on
aripiprazole completed the extension phase, compared to 8.1% for
those on lithium. A third arm of the study, completed by 8.5% of
participants, entailed treatment with placebo for 3 wk followed by
crossover to aripiprazole. Finally, the supplemental NDA
contained no references to additional studies, published or
unpublished, meeting inclusion criteria (Text S1) [29].
The two peer-reviewed publications included in our review report
the results of a single randomized trial (hereafter referred to as ‘‘the
Keck trial’’) implemented under the auspices of the Aripiprazole
Study Group and sponsored by the manufacturer of the drug,
Bristol-Myers Squibb Co. One publication describes the initial
26-wk double-blind phase [39], and the other its 74-wk extension
[40].Wealsoidentifieda posthocsubgroupanalysisofdata from the
Keck trial focused on participants diagnosed with the rapid-cycling
variant of bipolar disorder [44]. We also identified a separate trial
[45], also authored by Keck and colleagues, examining the efficacy
of aripiprazole in the treatment of acute manic episodes, with
outcomes assessed at 3 wk. Given the paucity of available evidence
on aripiprazole for the maintenance treatment of bipolar disorder,
we decided to review the Keck trial [39,40] in detail.
The Keck Trial
A total of 633 adult participants meeting DSM-IV criteria for
bipolar I disorder were enrolled in the Keck trial. A flow chart of
Figure 2. Clinical trials identified for review. These clinical trials were identified using a systematic search of ClinicalTrials.gov, the Cochrane
Central Register of Controlled Trials, the World Health Organization (WHO) International Clinical Trials Registry, and the Bristol-Myers Squibb Clinical
Trials Disclosure Web site, as well as a manual search of the supplemental new drug application submitted to the FDA to obtain an additional indication
for the use of aripiprazole in the maintenance treatment of bipolar disorder. The ‘‘duplicates’’ were each matched to published studies (see Figure 1).
doi:10.1371/journal.pmed.1000434.g002
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either have completed a prior 3-wk acute mania trial [45], met
eligibility criteria for a prior acute mania trial but declined
participation in that trial, or experienced a manic or mixed
episode within the prior 3 mo. The publication describing the 26-
wk double-blind phase [39] indicates that participants were
recruited from 76 sites in the U.S., Mexico, and Argentina (but
does not specify the numbers of sites within each country or the
numbers of patients from each site). Of the original enrollees, 567
entered the ‘‘stabilization phase,’’ which consisted of open-label
treatment with aripiprazole for 6–18 wk. Participants remained in
this phase until their Young Mania Rating Scale (YMRS) was #10
and their Montgomery-Asberg Depression Rating Scale (MADRS)
was #13 during four consecutive visits over a minimum of 6 wk.
206 participants completed the stabilization phase. Of these, 161
entered the double-blind phase. The supplemental NDA indicates
that participants who completed the stabilization phase and
entered randomization were derived from 45 sites in the U.S.
(n=124), three sites in Argentina (n=7), and two sites in Mexico
(n=30). These 161 participants were assigned either to an
intervention arm in which they continued taking aripiprazole at
the stabilizing dose (n=77 or 78; both numbers are reported [40])
or to a placebo arm in which aripiprazole was abruptly
discontinued and replaced with placebo (n=83). 39 (50% of the
77 or 78 who entered randomization) in the intervention arm and
28 participants (34%) in the placebo arm completed the 26-wk
double-blind phase. Time to relapse was described as longer for
participants treated with aripiprazole compared to those who were
switched to placebo. Mean times to relapse were not provided, but
the hazard ratio for relapse was given as 0.52 (95% confidence
interval [CI] 0.30–0.91). When time to relapse was partitioned
into manic versus depressive relapse, the difference in overall time
to relapse was found to be driven primarily by an effect on manic
relapse (23% relapse rate on placebo versus 8% relapse rate on
aripiprazole). No differences in time to depressive relapse (13%
versus 12%) or to mixed state relapse (6% versus 5%) were noted.
Keck and colleagues concluded that aripiprazole ‘‘was superior to
placebo in maintaining efficacy in patients with bipolar I disorder
with a recent manic or mixed episode who were stabilized and
maintained on aripiprazole treatment for 6 weeks’’ (p. 626) [39].
The extension phase of the Keck trial, published as a separate
paper [40], followed the remaining participants over the
subsequent 74 wk: 27 participants in the placebo group (of the
28 who completed the double-blind phase) and 39 participants in
the aripiprazole group. The authors concluded: ‘‘Over a 100-week
treatment period, aripiprazole monotherapy was effective for
relapse prevention in patients who were initially stabilized on
aripiprazole for 6 consecutive weeks, and it maintained a good
safety and tolerability profile’’ (p. 1480) [40]. Similar to the data
from the first 26 wk, time to manic relapse was reported to be
longer for the aripiprazole group (with no difference between
groups in time to depressive relapse).
Figure 3. Keck study participant flow. Participants had to complete the 6- to 18-wk stabilization phase before they were eligible for
randomization. After completion of the 26-wk double-blind phase, participants were invited to continue in the 74-wk extension phase.
doi:10.1371/journal.pmed.1000434.g003
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Although the Keck trial was the sole basis for aripiprazole
receiving an additional FDA-approved indication for the mainte-
nance treatment of bipolar disorder [29], we believe that reading
the Keck trial as supporting the use of aripiprazole for this
indication is an overinterpretation of the trial’s design and the data
it generated. First, the duration of the Keck trial was insufficient to
demonstrate prophylactic efficacy. Second, the double-blind phase
of the Keck trial was based on an enriched sample of patients who
had already responded to the medication during the stabilization
phase, thereby limiting generalizability of the trial’s findings.
Third, the randomized discontinuation design of the Keck trial
may conflate iatrogenic adverse effects of abrupt medication
discontinuation with the beneficial effects of short-term continu-
ation treatment. All of the putative benefit occurred during the
double-blind phase of the trial, and little improvement was gained
during the extension phase. And finally, the overall completion
rate was 1.3%, requiring unrealistic extrapolation to draw
meaningful conclusions. Keck et al. [39,40] mention lack of
generalizability as a potential limitation of the enrichment design,
but they do not discuss how these other limitations may have
compromised the trial’s internal validity.
The FDA’s review of the Keck trial identified other substantive
concerns, including the fact that the p-value for the primary
analysis changed from 0.02 to 0.10 when the statistical reviewer
excluded data from one of the trial’s two Mexican sites (where the
relapse rate among participants in the aripiprazole arm was lower
than the other trial sites) [46]. While of general concern, this and
other issues identified by the FDA are unrelated to our
methodological critiques. All of these factors undercut even a
cautious interpretation of the Keck trial as supporting the use of
aripiprazole for maintenance treatment of bipolar disorder. Below
we review each of these criticisms in detail.
Insufficient duration to demonstrate prophylactic
efficacy. In the open-label phase of the Keck trial, stability
was defined by whether or not a participant maintained YMRS
and MADRS scores in the asymptomatic range for at least 6
consecutive weeks. To meet this criterion, on average the trial
participants spent 89 d in the stabilization phase. Comparing their
own work to other randomized discontinuation studies of
maintenance treatment in bipolar disorder that required a
shorter duration of stability [47–49], Keck et al. describe their
stability criterion as ‘‘the most stringent criteria to date to define
stability’’ (p. 634) [39]. Intervention-arm participants who had
achieved stability on aripiprazole were then assigned to continue
with aripiprazole, and placebo-arm participants abruptly switched
to placebo, for the following 26 wk.
Contrary to the authors’ claims, we argue here that, given the
natural history of bipolar disorder, the design of the Keck trial was
unsuitable for evaluating the efficacy of aripiprazole in the
maintenance treatment of bipolar disorder. The episodic nature
of recurrent mania and depression require investigators to
randomize, enroll, and retain patients for a duration sufficient to
demonstrate maintenance and/or prophylactic efficacy. While
there is high interindividual variation, the median length of
untreated episodes has been reported to vary from 3–6 mo in
clinical trial settings and from 2–3 mo in epidemiological studies
[50], with depressive episodes typically lasting longer than manic
episodes [21,51]. Thus, even if one does not accept the other
methodological concerns we describe in this paper, the Keck trial,
with its stabilization criterion of 6 wk, could at best be used to
demonstrate a short-term benefit of continuation treatment in
preventing relapse of symptoms attributable to an ongoing acute
episode [52]. Demonstration of maintenance efficacy in preventing
recurrence of mood episodes would require benefit to be shown at
least 6 mo after the acute phase. 6 mo has been traditionally
recognized as the point at which continuation treatment becomes
maintenance treatment [10,11,12,52–54]. Appropriately, the
clinical review contained in the supplemental NDA describes a
meeting with the study’s sponsors in which the FDA’s Division of
Neuropharmacological Drug Products ‘‘expressed that the dura-
tion of the open-label stabilization phase defines duration of effect
and noted that an optimal study design would include a six month
open-label stabilization phase and randomized withdrawal of
patient subgroups at specified timepoints’’ (p. 9) [55]. The leading
textbook in the field suggests an even more stringent threshold
study duration: ‘‘Because the natural history of bipolar disorder is
for it to recur, on average, every 16–18 months, true prophylaxis
cannot be evaluated in 6 or 12 months’’ (p. 801) [21]. Although
somewhat controversial, the idea that demonstration of true
prophylactic efficacy requires a study duration longer than that
which has been typically utilized has been supported by other
leading researchers as well [11,52,56].
Limited generalizability due to the enriched
sample. Only participants who had responded to aripiprazole
in the stabilization phase of the trial were included in the double-
blind phase of the trial. Of the 567 participants who entered the
stabilization phase, only 206 completed it. Some of the
randomized participants received unblinded medication and
were therefore discontinued [29], so the double-blind efficacy
dataset consisted of 161 participants. This means that 361 of the
567 (74%) participants who entered the stabilization phase but
dropped out were excluded from randomization because of
adverse events, lack of efficacy, withdrawal of consent, and other
reasons as detailed in the publication—leaving behind a selected
group of participants who had responded favorably to aripiprazole
in the stabilization phase to be subsequently randomized. This
design could have the effect of biasing the trial’s findings away
from the null [57], and, even in the absence of such bias, the
results from this enriched sample cannot be generalized to the
majority of persons diagnosed with bipolar disorder. This
limitation of the randomized discontinuation design has long
been recognized by drug trialists [11,12,56,58–65] and is not
dissimilar to criticisms voiced about the first generation of
randomized trials evaluating the use of lithium for maintenance
treatment in bipolar disorder, i.e., that those study designs selected
preferentially for lithium-responsive variants of the disorder
[66,67].
Possible conflation of iatrogenic effects with beneficial
effects. The randomized discontinuation study design could
explain the putatively positive findings on preventing relapse even
in the absence of a true drug effect. In the Keck trial, the
randomization sample was enriched with participants who had
already responded to aripiprazole in the stabilization phase and
were therefore more likely to experience an iatrogenic relapse of
symptoms when aripiprazole was abruptly discontinued in the
double-blind phase. Abrupt discontinuation, or even abrupt partial
removal, of a drug used for maintenance has long been known to
provoke relapse in patients diagnosed with bipolar disorder [68–
77]. This ‘‘bipolar rebound phenomenon’’ has been most often
described for lithium, but it has also been observed in the setting of
abruptly withdrawn antiepileptic [78], antipsychotic [3,12,48,56,
78–80], and antidepressant medications [59,75,78,81] administered
to persons diagnosed with other mood and psychotic disorders. For
this reason, Geddes et al. specifically excluded studies with a
randomized discontinuation design from their systematic review
and meta-analysis of the long-term use of lithium in the treatment of
bipolar disorder [82].
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Keck trial might still be expected to show a higher relapse rate
early in the double-blind phase among participants assigned to the
placebo arm (compared to those assigned to the intervention arm),
and then similar relapse rates between study arms during the
extension phase. This particular design element appears to have
substantially influenced the outcome of the Keck trial, as is evident
from a comparison of data from the 26-wk double-blind phase
with data from the 74-wk extension phase. During the 26-wk
double-blind phase, 19 out of 83 participants (23%) in the placebo
arm experienced a manic relapse, whereas only four (5%) did so in
the subsequent 74-wk extension phase.
When relapse data from the 74-wk extension phase are
examined separately from those from the first 26 wk (Figure 3),
only four participants in the placebo arm experienced a relapse to
mania, compared to 3 participants in the intervention arm (4.8%
versus 3.8%). This information is not explicitly presented in either
paper and can only be discerned by comparing the papers side by
side and calculating the differences by hand. Figure 4 in the 74-wk
extension phase publication (p. 1486) [40] shows that 28% of
participants in the placebo arm relapsed to mania over 100 wk of
follow up. Given n=83 in the placebo arm, this suggests 23
participants in the placebo arm relapsed to mania over 100 wk of
follow up. Because 19 participants in the placebo arm relapsed to
mania in the first 26 wk (Figure 5 in the 26-wk double-blind phase
publication [p. 531] [39]), this means four participants relapsed to
mania during the 74-wk extension phase. We employed similar
reasoning to calculate the number of participants who relapsed to
mania in the intervention arm, as well as the number of
participants who relapsed to depressive and mixed states. Similar
patterns are observed for relapse to depression and relapse to
mixed state for the placebo and aripiprazole arms. Thus, virtually
all of the reported placebo-aripiprazole difference in relapse
occurred during the first 26 wk of the trial.
Limitations of the low completion rate. Only seven of 39
(18%) aripiprazole-treated participants and five of 27 (19%)
placebo-treated participants completed the 74-wk extension phase.
The low completion rate in the treatment arm is especially striking
given that only participants who had proven to be responders in
the initial stabilization phase were included in the double-blind
and extension phases and that the placebo group matched the
aripiprazole group in terms of trial completion. Out of the 633
participants who entered the trial, after excluding the 83 who were
switched to placebo, only seven aripiprazole-treated participants
completed the 100-wk trial, for a completion rate among
aripiprazole-treated participants of less than 1.3%. This is not
explicitly noted anywhere in the paper [40]. Keck et al. [40]
acknowledge that only 12 participants completed the trial, but the
smaller denominator used for comparison is the number of
participants who entered the 74-wk extension phase rather than all
participants who entered the trial.
We argue that drawing meaningful conclusions from a trial with
an overall completion rate of less than 1.3% is an inappropriate
undertaking. The completion rate substantially limits generaliz-
ability of the trial’s findings, as trial completers very likely were
dissimilar to the enrolled and/or randomized participant pools.
The meaningful differences between completers and noncompl-
eters were demonstrated in a randomized trial of divalproex versus
Figure 4. Publications citing the Keck study. These publications were identified using Web of Science(R) Science Citation Index Expanded.
Those that discussed the Keck study in relation to the maintenance treatment of bipolar disorder were evaluated on three quality indicators, as
shown.
doi:10.1371/journal.pmed.1000434.g004
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who completed the trial had milder symptoms at baseline and a
less severe lifetime illness course [84]. Keck et al. identify the low
completion rate in the extension phase as a potential limitation but
appeal to the low completion rates observed in other maintenance
trials [47,48] to support the generalizability of their results. In
contrast, we view the similar completion rates observed in other
long-term studies as similarly raising concerns about how to draw
inferences from these trials to inform routine clinical practice. Still,
we observe that other investigators have successfully implemented
long-term studies in this patient population with greater rates of
completion: for example, earlier studies of lithium in the treatment
of affective disorders demonstrated completion rates of 92.9%
(26/28) [85] and 73.2% (74/101) [86] among lithium-treated
participants.
Impact of the Keck Trial on the Literature
Our citation search protocol identified 80 articles that cited the
results from the 26-wk double-blind phase [39] and 48 articles that
cited the results of the 74-wk extension phase [40]. After
eliminating duplicates, the two publications from the Keck trial
garnered 104 subsequent citations in total. Of these citing articles,
24 did not contain any mention of the Keck trial in relation to
long-term or maintenance treatment of bipolar disorder and were
excluded from further analysis (Figure 4). Double-coding revealed
a high degree of inter-rater agreement on the quality assessment
measures. There was 100% agreement on whether the publica-
tions were classified as mentioning aripiprazole for maintenance
treatment. Among the double-coded publications mentioning
maintenance treatment, there was 100% agreement on whether
quantitative data and limitations were mentioned. There was one
disagreement about whether adverse events were mentioned,
yielding a kappa coefficient of 0.75 (95% CI 0.05–0.95). The
overall kappa coefficient was 0.95 (95% CI 0.73–0.99).
Of the 80 articles that cited the Keck trial in reference to
maintenance treatment of bipolar disorder, only 20 (25%)
presented any quantitative data from the Keck trial; the remainder
reported qualitative statements only (e.g., ‘‘Aripiprazole signifi-
cantly delayed the time to relapse into a new mood episode in
patients with bipolar I disorder over both 26 and 100 weeks of
treatment.’’ [87]). 24 publications (30%) mentioned any of the
adverse events reported in the trial. Only four (5%) made any
mention of study limitations.
Among the articles identified through our citation search
protocol were eight literature reviews [88–95] and three bipolar
treatment guidelines [15,96,97] that specifically discussed the use
of aripiprazole in the treatment of bipolar disorder. Because
review articles and treatment guidelines can be particularly
influential in shaping policy and prescribing behavior, we chose
to highlight these in our discussion (Table 1). The evidence
summaries employed the methodologies of consensus panel (n=3),
narrative review (n=6), or systematic review (n=2). Ten of the 11
reviews and treatment guidelines contained a financial disclosure
related to Bristol-Myers Squibb.
Overall, the eight reviews were favorable in their assessment as
to the putative efficacy of aripiprazole in the maintenance
treatment of bipolar disorder. Solely on the basis of the results
of the Keck trial, the Texas Medication Algorithm Project update
listed aripiprazole as having ‘‘level 2’’ evidence (out of five levels of
quality, with level 1 being the highest-quality) for maintenance
treatment of bipolar disorder [15]. The Canadian Network for
Mood and Anxiety Treatments and International Society for
Bipolar Disorders recommended aripiprazole as first-line mainte-
nance treatment of bipolar disorder, although it is noted that this is
‘‘mainly for preventing mania’’ (p. 235) [96]. This treatment
recommendation was based on the Keck trial, along with a 30-wk
pediatric bipolar trial that has only been published in abstract
form [98]. The British Association for Psychopharmacology (BAP)
based its positive endorsement of aripiprazole for relapse
prevention solely on the Keck trial [97]. Contrary to the criticisms
we described earlier, the BAP guidelines note, ‘‘Acute withdrawal
of the active agent did not produce an excess of early relapse in
this study’’ (p. 26).
Discussion
Our evaluation of the evidence base supporting the use of
aripiprazole for the maintenance treatment of bipolar disorder
reveals that the justification for this practice relies on the results
from a single trial by Keck and colleagues published in two peer-
reviewed journal articles [39,40]. The methodology and reporting
of the Keck trial are such that the results cannot be generalized to
inform the treatment of most patients with bipolar disorder.
Published interpretations of the data notwithstanding, in our
opinion the Keck trial does not provide data to support the use of
aripiprazole in the maintenance treatment of bipolar disorder.
This lack of robust evidence of benefit should be weighed against
the potential for long-term harms that have been described with
other antipsychotic medications [3] and adverse events related to
aripiprazole use, including tremor, akathisia, and significant
weight gain [39]. Our concern about the critical imitations in
this trial is further accentuated by the apparent widespread use of
aripiprazole as a first-line agent for the maintenance treatment of
bipolar disorder [31,32].
Although we appreciate that the unique clinical features of
bipolar disorder make controlled study extremely difficult
[67,84,99–103], many of the weaknesses we document stem
from the use of the randomized discontinuation design. Further
study is needed in order to determine whether the problems
described in this particular case are also more widely applicable
to other continuation or maintenance treatment studies in bipolar
disorder. We find unpersuasive the argument that a randomized
discontinuation study such as this is valuable because it reflects
common clinical practice [104,105]. The two-arm, parallel
randomized controlled trial may yield information that is more
clinically useful than the discontinuation design. Under the
parallel design, data from all participants (not just those who
demonstrated an acute response) would contribute to our
understanding of the drug’s short- and long-term efficacy: one
of two medications (or placebo) would be given to participants in
the acute phase, and they would be followed throughout the
continuation and maintenance phases (and beyond) to document
response to treatment. (This study design, as well as the other
study designs we describe, clearly could be used to study
nonpharmacological treatments, including evidence-based psy-
chotherapies. However, because this paper has emphasized
discussion about pharmacologic treatments, we use the phrase
‘‘medication’’ for simplicity.) A two-arm, parallel randomized
controlled trial of sufficient duration would directly answer the
substantive research question, ‘‘Does aripiprazole treat symptoms
to remission and prevent recurrent episodes when given to
patients diagnosed with bipolar disorder presenting in a manic or
mixed state?’’ This is clearly different from the question answered
by the discontinuation design, ‘‘Among patients diagnosed with
bipolar presenting in a manic or mixed state who have achieved a
reasonable symptomatic improvement after being given aripipra-
zole, should aripiprazole be continued to maintain the initial
improvement?’’ [106].
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proportion of (acutely ill) study participants would be subjected to
placebo for the full duration of the trial, exactly the ethical issue
that the discontinuation design was intended to address [107,108].
Keck et al. [39] stated that they sought to minimize the extent to
which stabilized participants were administered placebo. Yet their
study could have been modified to diminish its exposure to the
weaknesses that we have described above. First, the duration of
stability required prior to randomization could be lengthened.
One likely cost of this design modification is that the proportion of
participants actually randomized would decrease further [109]. A
second modification would be to gradually taper the discontinu-
ation of medication among participants randomized to receive
placebo. In previously published randomized discontinuation
studies, medications administered during the open-label phase
were tapered over a period of 2 to 3 wk rather than abruptly
discontinued [47,83]. Greenhouse et al. [59] suggest implementing
the taper over several months.
Table 1. Treatment guidelines and reviews of aripiprazole for the treatment of bipolar disorder.
Author, Year,
Country
Financial Disclosure
Related to Bristol-
Myers Squibb Methods Quality Indicators
a Narrative Recommendation
ABC
Goodwin, 2009,
Great Britain [97]
Yes Consensus panel No No No ‘‘Aripiprazole was more effective than placebo after acute
and continuation treatment of mania with aripiprazole: no
effect on depression was discernable. Acute withdrawal of
the active agent did not produce an excess of early relapse
in this study.’’ (positive)
Yatham, 2009,
Canada [96]
Yes Consensus panel No No No ‘‘Given that efficacy was shown primarily for mania,
aripiprazole is included as a first-line maintenance treatment
for bipolar disorder for the treatment and prevention of
mania.’’ (positive)
Suppes, 2005,
United States [15]
Yes Consensus panel No No No ‘‘Aripiprazole is recommended based on a randomized,
double-blind, placebo-controlled, 6-month maintenance
study in which patients received open-label aripiprazole
until stable, then were randomized to either placebo or
aripiprazole for the 6-month follow-up.’’ (positive)
Garcia-Amador,
2006, Spain [93]
Yes Narrative review Yes Yes No ‘‘These data support the decision by the US FDA to approve
aripiprazole for the maintenance treatment of bipolar
patients, beyond the treatment of acute mania.’’ (positive)
McIntyre, 2007,
Canada [91]
Yes Narrative review Yes Yes No ‘‘Aripiprazole is established as being efficacious in acute
mania and for the prevention of manic relapse in BD.
Aripiprazole efficacy is confirmed on primary and secondary
efficacy parameters.’’ (positive)
Fagiolini, 2008,
United States [94]
Yes Narrative review Yes Yes No ‘‘This 100-week study showed a significantly longer time to
relapse with aripiprazole when compared with placebo.’’
(positive)
McIntyre, 2007,
Canada [90]
Yes Narrative review Yes Yes No ‘‘A single, randomized, double-blind, parallel group,
placebo-controlled study reported on the safety and efficacy
of aripiprazole in preventing relapse of a mood episode in
recently manic or mixed episode patients with bipolar I
disorder.’’ (positive)
Ulusahin, 2008,
Turkey [95]
None disclosed Narrative review Yes Yes No ‘‘One double-blind, randomized, placebo controlled clinical
trial of 100-week aripiprazole monotherapy, which is the
longest clinical trial among the trials conducted in bipolar
disorder among the second-generation antipsychotics,
showed that aripiprazole was effective for relapse
prevention in bipolar patients.’’ (positive)
Muzina, 2009,
United States [89]
Yes Narrative review Yes Yes No ‘‘The results from a 100-week study of aripiprazole for the
prevention of bipolar I episodes represent the longest
maintenance study since early lithium trials and support the
use of aripiprazole as maintenance treatment, primarily
against manic relapses.’’ (positive)
Fountoulakis, 2009,
Greece [88]
Yes Systematic review Yes Yes Yes ‘‘Recent reviews suggest that aripiprazole is efficacious in
acute mania and in the maintenance treatment of bipolar
disorder, with a favourable safety and tolerability profile,
with minimal propensity for clinically significant weight gain
and metabolic disruption.’’ (positive)
McIntyre, 2010,
Canada [92]
Yes Systematic review Yes Yes Yes ‘‘The available evidence supports the efficacy and
tolerability of aripiprazole in the maintenance treatment of
bipolar disorder.’’ (positive)
aA, reported any quantitative data; B, reported any adverse events; C, reported any study limitations.
BD, bipolar disorder.
doi:10.1371/journal.pmed.1000434.t001
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alternatives have been suggested. Greenhouse et al. [59] proposed
an alternative randomization scheme in which study participants
are randomized to one of six treatment strategies. In the acute
phase of treatment, study participants would receive one of two
medications. In the maintenance phase of treatment, study
participants would either remain on the medication initiated
during the acute phase, be switched (gradually) to the alternative
medication, or be switched (gradually) to placebo. This innovative
study design would address the substantive research question,
‘‘Which treatment strategy is better in controlling and preventing
the recurrence of depression?’’ (p. 318) [59]. A pure prophylactic
design has also been recommended [10,12,100], in which patients
previously diagnosed with a recurrent mood disorder would be
enrolled during a medication-free remission period. Then, while
participants are in remission, they would be offered one of two
medications (or placebo). All participants would be followed in the
study for a prespecified duration, and the treatment arms would be
compared in terms of time to recurrence of a mood episode. This
design would avoid the previously described error of possibly
conflating beneficial treatment effects with iatrogenic adverse
effects of abrupt medication discontinuation. However, as noted
by Goodwin, Whitman, and Ghaemi [12], the failure of the
divalproex study by Bowden et al. [83] was partly attributed to its
enrollment of participants with low severity of illness [84]—and it
was the last study to utilize the lithium-era prophylaxis design.
We recognize that the proposed study designs will be regarded
by some as too costly or infeasible. Although some have suggested
that a study with selected limitations may be useful in guiding
clinical practice [104], we would disagree with this argument. The
current ‘‘anti-Hippocratic’’ state of psychopharmacological prac-
tice described by Ghaemi [56,110] raises questions about the
extent to which research with substantive limitations is appropri-
ately interpreted with conservative sensibilities. These concerns are
borne out in our data. Thomson Reuters Essential Science
Indicators(SM) places the 26-wk double-blind phase publication in
the top 1%, and the 74-wk extension phase publication in the top
1%–2%, of papers published in the fields of psychiatry and
psychology. Thus, by our conservative estimates, the Keck trial
could be regarded as relatively influential. More importantly, we
found that the Keck trial was cited uncritically by a subsequent
generation of authors, through treatment guidelines, reviews, and
other publications. All failed to note the consequences of abrupt
and premature discontinuation of antimanic medication, especially
during the vulnerable continuation period. The uncritical manner
in which the Keck trial has been cited is reminiscent of the ‘‘echo
chamber’’ effect described by Carey et al. [111] in their assessment
of the now-discredited use of gabapentin in the treatment of
bipolar disorder. Although the analogy is somewhat limited as
there were no reportedly positive double-blind trials examining the
use of gabapentin for this indication, we document a similar
pattern of uncritical citations of the primary evidence regarding
aripiprazole in the maintenance treatment of bipolar disorder.
Of further concern regarding the uncritical citation of the Keck
trial’s claims is that ten of the 11 treatment guidelines and review
articles in our sample contained a financial disclosure related to
the drug’s manufacturer, Bristol-Myers Squibb Co. Financial
conflicts of interest are highly prevalent across a wide range of
medical subfields [112], and while they are known to be associated
with recommendations in review articles [113], there is no
systematic research documenting their influence on clinical
practice guideline recommendations [114]. However, financial
conflicts of interest have been found to be associated with biased
reporting of outcomes in randomized trials [115,116], which serve
as the evidence upon which treatment guideline recommendations
are based.
In summary, we provide here a critical appraisal of the available
evidence regarding the use of aripiprazole for the maintenance
treatment of bipolar disorder. The available evidence consists of a
single trial by Keck et al. [39,40], which is subject to several
substantive methodological limitations but has nonetheless been
cited uncritically in the ensuing scientific literature. Several
alternative modifications or study designs may improve the
probability of generating more useful data from studies in this
vulnerable patient population to inform the treatment of similar
patients in the future. We are concerned that the publication and
apparently uncritical acceptance of this trial may be diverting
patients away from more effective treatments.
Supporting Information
Table S1 Published studies excluded from review. These five
published studies were not included in the review because they
were open-label, examined the use of aripiprazole as adjunctive
treatment or for acute mania, or lacked sufficient duration.
Found at: doi:10.1371/journal.pmed.1000434.s001 (0.03 MB
DOC)
Table S2 Clinical trial registry studies excluded from review.
These 12 studies were not included in the review because they
were open-label, examined the use of aripiprazole as adjunctive
treatment or for acute mania, or lacked sufficient duration.
Found at: doi:10.1371/journal.pmed.1000434.s002 (0.04 MB
DOC)
Text S1 Approval package for: 21-436/S-005 & S-008 & 21-
713/S-003. Washington (D.C.): Center for Drug Evaluation and
Research, U.S. Food and Drug Administration; 2005. This
supplemental New Drug Application (sNDA), which provides for
the use of aripiprazole as maintenance therapy in bipolar I
disorder, was obtained through a U.S. Freedom of Information
Act request.
Found at: doi:10.1371/journal.pmed.1000434.s003 (4.92 MB
PDF)
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Background. Bipolar disorder (manic depression) is a
serious, long-term mental illness that affects about 1% of
adults at some time during their life. It usually develops in
late adolescence or early adulthood and affects men and
women from all backgrounds. People with bipolar disorder
experience wild mood swings that interfere with daily life
and damage relationships. During ‘‘manic’’ episodes, which
can last several months if untreated, they may feel euphoric
(‘‘high’’), energetic, or irritable. They may be full of ambitious
plans, feel creative, and spend money recklessly. They can
also have psychotic symptoms—they may see or hear things
that are not there. During depressive episodes, affected
individuals may feel helpless, worthless, and suicidal.
Treatments for bipolar disorder include drugs to stabilize
mood swings (for example, lithium and anticonvulsant
medications), antidepressants to treat depressive episodes,
and antipsychotic drugs to treat manic episodes.
Psychotherapy can also help and patients can be taught to
recognize the signs of approaching manic or depressive
episodes and the triggers for these episodes.
Why Was This Study Done? Treatment of bipolar disorder
is divided into three phases: acute treatment lasting about 2
months to achieve remission, continuance treatment lasting
from months 2 through 6 to prevent relapse, and long-term
maintenance treatment to prevent recurrence. Second-
generation (atypical) antipsychotics are widely used for
acute treatment of manic episodes but are also used for
maintenance treatment. For example, the atypical
antipsychotic aripiprazole, which gained US approval for
this indication in 2005, is now a popular choice among
clinicians for treating bipolar disorder. But how much
evidence is there to support aripiprazole’s use in the
maintenance treatment of bipolar disorder? Here, the
researchers systematically search the published literature
for double-blind randomized controlled trials of aripiprazole
for this indication, critically analyze the quality of these trials,
and undertake a citation search to investigate how the
results of these trials have been disseminated in the scientific
literature. In double-blind randomized controlled trials,
patients are randomly assigned to receive a test drug or a
control (generally, placebo), and the effects of these drugs
compared; patients in the trial, and physicians administering
treatments, would not know who is receiving the test drug
or control until the trial is completed.
What Did the Researchers Do and Find? The
researchers’ search for reports of double-blind randomized
controlled trials of aripiprazole for the maintenance
treatment of bipolar disorder using predefined criteria
identified only two publications, both describing a single
trial—the Keck trial. Critical review of this trial identified four
issues that limit its interpretation for supporting aripiprazole
as a maintenance therapy: the trial was too short to
demonstrate maintenance efficacy; all the trial participants
had responded well to aripiprazole as an acute treatment so
the generalizability of the trial’s results was limited; the trial
design meant that some of the apparent beneficial
treatment results could have reflected the adverse effects
of abrupt medication discontinuation in the control group;
and the trial had a low completion rate. The researchers’
citation search identified 80 publications that cited the Keck
trial in discussions of the use of aripiprazole for maintenance
treatment of bipolar disorder. Only a quarter of these papers
presented any numerical data from the trial, only a third
mentioned any of the reported adverse events, and only four
papers mentioned the trial’s limitations.
What Do These Findings Mean? This evaluation of the
evidence base supporting the use of aripiprazole for the
maintenance treatment of bipolar disorder shows that the
justification for this practice relies on the results of one
published trial. Moreover, the methodology and reporting of
this trial mean that its results cannot easily be generalized to
inform the treatment of most patients with bipolar disorder.
Worryingly, the researchers’ citation search indicates that the
Keck trial has been cited uncritically in the ensuing scientific
literature. Although the unique features of bipolar disorder
make it hard to undertake controlled studies of treatment
options, the researchers express concern that ‘‘the
publication and apparently uncritical acceptance of this
trial may be diverting patients away from more effective
treatments’’.
Additional Information Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000434.
N The US National Institute of Mental Health has detailed
information on bipolar disorder, including an Easy to Read
booklet (in English and Spanish)
N The UK National Health Service Choices website provides
information on all aspects of bipolar disorder
N The UK charity Mind has information on bipolar disorder
and provides links to other useful organizations
N MedlinePlus has links to further information on ><bipolar
disorder (in English and Spanish)
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